Metastatic Merkel Cell Carcinoma

9 clinical trials · Condition

Record	Firm	Date
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial (NCT07576725)	Fred Hutchinson Cancer Center	2026-09-01
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (NCT05896839)	National Cancer Institute (NCI)	2024-07-24
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial (NCT05947500)	National Cancer Institute (NCI)	2024-05-21
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (NCT05269381)	Mayo Clinic	2022-03-31
Targeted Therapy and Avelumab in Merkel Cell Carcinoma (NCT04261855)	Melanoma and Skin Cancer Trials Limited	2020-10-08
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (NCT03816332)	National Cancer Institute (NCI)	2019-11-08
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) (NCT03599713)	Incyte Corporation	2019-02-25
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma (NCT03304639)	National Cancer Institute (NCI)	2018-06-12
Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC) (NCT03089658)	Merck KGaA, Darmstadt, Germany

Every clearance here is in the API, with alerts when new ones post.